tradingview.comAug 24$KROS

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

Keros Therapeutics (KROS) received a $20M milestone payment from Takeda for the first patient dosed in the Phase III ELRiSE study. The company has no marketed products and limited revenue, but the payment adds financial flexibility. KROS will distribute 25% of the proceeds to stockholders and use the rest to advance its rinvatercept program. Cash reserves were $257.6M at June 30, 2026, with shares down 46.8% year-to-date.

Original reporting

tradingview.com

Published Aug 24, 2026, 4:53 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 24, 2026, 10:10 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak — source image — Source · tradingview.com

Decision brief

The 30-second read

$KROSNeutralLow

Why it matters

The $20 M milestone improves cash runway to 2028 but does not alter the company’s revenue‑visibility challenges.

Market read

Milestone cash is a material event for KROS, yet the lack of recurring revenue keeps overall market impact limited.

What to watch

Potential upcoming regulatory hurdles for rinvatercept and competition from SRPT and PTCT in DMD.

Relevance 6/10Novelty 6/10Timing: on Aug 24 2026

Background

Keros Therapeutics (KROS) is a clinical‑stage biotech without any marketed products, relying on collaboration payments.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$KROSNeutralMedium confidence

Context

Keros Therapeutics received a $20 million development milestone from Takeda after first‑patient dosing in the Phase III ELRiSE study.

Expected impact

Limited short‑term upside; price may stabilize modestly.

Evidence & confidence

Milestone cash is material for a cash‑burning microcap, yet revenue remains absent and future payments are uncertain.

Market effects

Sector

Highlights continued reliance of biotech microcaps on partnership milestones.

Regional

Minimal; impact confined to US‑listed biotech sector.

Global

Low; only relevant to investors tracking partnership‑driven cash flows.

Counterpoint

What could challenge this read

The milestone may be over‑valued by the market; cash burn could outweigh short‑term liquidity benefits.

Key entities

company
Keros Therapeutics
US‑listed biotech receiving the milestone.
company
Takeda
Partner providing the development milestone.

Read at source ← All news

$KROSMed

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results

Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results • First patient dosed in Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy in September 2026 • Nominated KER-206, a novel ligand trap desi

SEC EDGAR 8-KNov 5

$KROSLow

Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage

Keros Therapeutics (NASDAQ:KROS) initiated a Phase II study of rinvatercept for Duchenne muscular dystrophy (DMD), expecting data in early 2027. The treatment aims to increase muscle regeneration. Keros also plans an ALS trial in 2027, targeting muscle preservation. The company will use DEXA scans and functional assessments to evaluate progress.

finance.yahoo.comOct 22

$IRONMedAI 8/10

A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

Disc Medicine's Phase 3 trial for a rare light-sensitivity disorder met all endpoints, shares rose 38.86%. Silence Therapeutics agreed to a $1.3B acquisition by Merck KGaA at a 130% premium, shares up 125.58%. Other rare blood disorder-focused companies also saw gains. Disc plans FDA resubmission by 2026 end, Silence deal expected Q1 2027.

prnewswire.comOct 20

$KROSMed

Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda

Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda LEXINGTON, Mass., September 29, 2026, (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing an

SEC EDGAR 8-KSep 29

$KROSMedAI 8/10

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD • Initial data expected in the first half of 2027 LEXINGTON, Mass., September 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: K

SEC EDGAR 8-KSep 28

$CAPRHighAI 8/10

CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review

Capricor (CAPR) stock rose after-hours as the company reaffirmed confidence in its Deramiocel treatment ahead of a November 22 decision. The HOPE-3 trial met its primary endpoint, showing a 1.1-point improvement in upper limb function. Capricor reported a Q3 net loss of $42.7 million and $198.5 million in cash reserves. Retail sentiment on StockTwits was extremely bullish, with mixed opinions on approval odds. CAPR stock is down 69% year-to-date.

finance.yahoo.comNov 10